Isolation of Primary Hepatocytes for Testing Tumor Penetrating Peptides.
Interfering peptides
Liver cancer
Tumor penetrating peptides
Journal
Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969
Informations de publication
Date de publication:
2022
2022
Historique:
entrez:
12
11
2021
pubmed:
13
11
2021
medline:
8
1
2022
Statut:
ppublish
Résumé
Methods for isolation of human primary cells is an important tool to be able to test the effect of several drugs for the treatment of diseases. Protocols have been described for the isolation of healthy and tumoral hepatocytes; however, the quality and the amount of the isolated cells is not satisfactory. We describe here protocols for the isolation of healthy and tumoral hepatocytes as well as the use of tumor penetrating and interfering peptides as new therapeutics. Peptides are showed to be safe drugs and taking into account recent improvements in peptide administration, biodelivery, and bioavailability. Tumor penetrating peptides fused to an interfering peptide have a great potential to become therapeutic agents.
Identifiants
pubmed: 34766304
doi: 10.1007/978-1-0716-1752-6_26
doi:
Substances chimiques
Cell-Penetrating Peptides
0
Peptides
0
Pharmaceutical Preparations
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
413-427Informations de copyright
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Lu XY, Xi T, Lau WY, Dong H, Zhu Z, Shen F et al (2011) Hepatocellular carcinoma expressing cholangiocyte phenotype is a novel subtype with highly aggressive behavior. Ann Surg Oncol 18:2210–2217
pubmed: 21308485
Global Burden of Disease Liver Cancer C, Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA et al (2017) The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and National Level: results from the global burden of disease study 2015. JAMA Oncol 3:1683–1691
European Association for the Study of the Liver (2018) Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 69:182–236
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108
pubmed: 25651787
pmcid: 25651787
Fattovich G, Stroffolini T, Zagni I, Donato F (2004) Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127:S35–S50
pubmed: 15508101
Llovet JM, Bru C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19:329–338
pubmed: 10518312
Simon-Gracia LSE, Parizot C, Brossas JY, Loisel S, Teesalu T, Conti F, Charllotte F, Scatton O, Aoudjehane L, Rebollo A (2020) Bi-functional therapeutic peptides for targeting malignant B cells and hepatocytes: proof of concept in chronic lymphocytic leukemia. Adv Ther 3:1–13
Nambotin SB, Lefrancois L, Sainsily X, Berthillon P, Kim M, Wands JR et al (2011) Pharmacological inhibition of Frizzled-7 displays anti-tumor properties in hepatocellular carcinoma. J Hepatol 54:288–299
pubmed: 21055837
Zan Y, Dai Z, Liang L, Deng Y, Dong L (2019) Co-delivery of plantamajoside and sorafenib by a multi-functional nanoparticle to combat the drug resistance of hepatocellular carcinoma through reprograming the tumor hypoxic microenvironment. Drug Deliv 26:1080–1091
pubmed: 31735093
pmcid: 6882497
Wang X, Wu F, Li G, Zhang N, Song X, Zheng Y et al (2018) Lipid-modified cell-penetrating peptide-based self-assembly micelles for co-delivery of narciclasine and siULK1 in hepatocellular carcinoma therapy. Acta Biomater 74:414–429
pubmed: 29787814
Zhao H, Wu M, Zhu L, Tian Y, Wu M, Li Y et al (2018) Cell-penetrating peptide-modified targeted drug-loaded phase-transformation lipid nanoparticles combined with low-intensity focused ultrasound for precision theranostics against hepatocellular carcinoma. Theranostics 8:1892–1910
pubmed: 29556363
pmcid: 5858507
Jin C, Bai L, Lin L, Wang S, Yin X (2018) Paclitaxel-loaded nanoparticles decorated with bivalent fragment HAb18 F(ab’)2 and cell penetrating peptide for improved therapeutic effect on hepatocellular carcinoma. Artif Cells Nanomed Biotechnol 46:1076–1084
pubmed: 28776396
Liu Y, Wu X, Gao Y, Zhang J, Zhang D, Gu S et al (2016) Aptamer-functionalized peptide H3CR5C as a novel nanovehicle for codelivery of fasudil and miRNA-195 targeting hepatocellular carcinoma. Int J Nanomedicine 11:3891–3905
pubmed: 27574422
pmcid: 4990390
Wang G, Jia T, Xu X, Chang L, Zhang R, Fu Y et al (2016) Novel miR-122 delivery system based on MS2 virus like particle surface displaying cell-penetrating peptide TAT for hepatocellular carcinoma. Oncotarget 7:59402–59416
pubmed: 27449085
pmcid: 5312320
Wang J, Wang H, Li J, Liu Z, Xie H, Wei X et al (2016) iRGD-decorated polymeric nanoparticles for the efficient delivery of Vandetanib to hepatocellular carcinoma: preparation and in vitro and in vivo evaluation. ACS Appl Mater Interfaces 8:19228–19237
pubmed: 27381493
Xie HG, Frueh FW (2005) Pharmacogenomics steps toward personalized medicine. Per Med 2:325–337
pubmed: 29788578
Watters JW, McLeod HL (2003) Cancer pharmacogenomics: current and future applications. Biochim Biophys Acta 1603:99–111
pubmed: 12618310
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674
pubmed: 21376230
Teesalu T, Sugahara KN, Ruoslahti E (2013) Tumor-penetrating peptides. Front Oncol 3:216–221
pubmed: 23986882
pmcid: 3753659
Ruoslahti E (2017) Tumor penetrating peptides for improved drug delivery. Adv Drug Deliv Rev 110–111:3–12
pubmed: 27040947
Zanuy D, Kotla R, Nussinov R, Teesalu T, Sugahara KN, Aleman C et al (2013) Sequence dependence of C-end rule peptides in binding and activation of neuropilin-1 receptor. J Struct Biol 182:78–86
pubmed: 23462097
pmcid: 6146283
Teesalu T, Sugahara KN, Kotamraju VR, Ruoslahti E (2009) C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc Natl Acad Sci U S A 106:16157–16162
pubmed: 19805273
pmcid: 2752543
Simon-Gracia L, Hunt H, Teesalu T (2018) Peritoneal Carcinomatosis targeting with tumor homing peptides. Molecules 23:150–158
Braun GB, Sugahara KN, Yu OM, Kotamraju VR, Molder T, Lowy AM et al (2016) Urokinase-controlled tumor penetrating peptide. J Control Release 232:188–195
pubmed: 27106816
pmcid: 5359125
Sugahara KN, Scodeller P, Braun GB, de Mendoza TH, Yamazaki CM, Kluger MD et al (2015) A tumor-penetrating peptide enhances circulation-independent targeting of peritoneal carcinomatosis. J Control Release 212:59–69
pubmed: 26071630
pmcid: 4508207
Willmore AM, Simon-Gracia L, Toome K, Paiste P, Kotamraju VR, Molder T et al (2016) Targeted silver nanoparticles for ratiometric cell phenotyping. Nanoscale 8:9096–9101
pubmed: 26646247
pmcid: 4850089
Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Girard OM et al (2009) Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 16:510–520
pubmed: 19962669
pmcid: 2791543
Sugahara KN, Braun GB, de Mendoza TH, Kotamraju VR, French RP, Lowy AM et al (2015) Tumor-penetrating iRGD peptide inhibits metastasis. Mol Cancer Ther 14:120–128
pubmed: 25392370
Simon-Gracia L, Scodeller P, Fuentes SS, Vallejo VG, Rios X, San Sebastian E et al (2018) Application of polymersomes engineered to target p32 protein for detection of small breast tumors in mice. Oncotarget 9:18682–18697
pubmed: 29721153
pmcid: 5922347
Paasonen L, Sharma S, Braun GB, Kotamraju VR, Chung TD, She ZG et al (2016) New p32/gC1qR ligands for targeted tumor drug delivery. Chembiochem 17:570–575
pubmed: 26895508
pmcid: 5433940
Fogal V, Zhang L, Krajewski S, Ruoslahti E (2008) Mitochondrial/cell-surface protein p32/gC1qR as a molecular target in tumor cells and tumor stroma. Cancer Res 68:7210–7218
pubmed: 18757437
pmcid: 2562323
Bruzzoni-Giovanelli H, Alezra V, Wolff N, Dong CZ, Tuffery P, Rebollo A (2018) Interfering peptides targeting protein-protein interactions: the next generation of drugs? Drug Discov Today 23:272–285
pubmed: 29097277
Arrouss I, Nemati F, Roncal F, Wislez M, Dorgham K, Vallerand D et al (2013) Specific targeting of caspase-9/PP2A interaction as potential new anti-cancer therapy. PLoS One 8:e60816
pubmed: 23637769
pmcid: 3634037
Arrouss I, Decaudin D, Choquet S, Azar N, Parizot C, Zini JM et al (2015) Cell penetrating peptides as a therapeutic strategy in chronic lymphocytic leukemia. Protein Pept Lett 22:539–546
pubmed: 25687226
Tian L, Zhang X, Nemati F, Vallerand D, Raimonide C, Decaudin D, Jy B, Jm Z, SylvainChoquet S, Mf S, Feillant M, Lester K, Loisel S, Rebollo A (2016) Identification of Ras/Raf binding site and design of interfering peptides with potential clinical application. Integrative Mol Med 36:1–9
Dong CZ, Bruzzoni-Giovanelli H, Yu Y, Dorgham K, Parizot C, Zini JM et al (2020) Identification of peptides interfering with the LRRK2/PP1 interaction. PLoS One 15:e0237110
pubmed: 32790695
pmcid: 7425875
Dominguez-Berrocal L, Cirri E, Zhang X, Andrini L, Marin GH, Lebel-Binay S et al (2019) New therapeutic approach for targeting hippo Signalling pathway. Sci Rep 9:4771–4783
pubmed: 30886324
pmcid: 6423280
Pierrot C, Zhang X, Zanghi G, Freville A, Rebollo A, Khalife J (2018) Peptides derived from Plasmodium falciparum leucine-rich repeat 1 bind to serine/threonine phosphatase type 1 and inhibit parasite growth in vitro. Drug Des Devel Ther 12:85–88
pubmed: 29386885
pmcid: 5765974
Tian L, Zhang X, Haesen D, Bravo J, Fominaya J, Choquet S, Zini J, Loisel S, Waelkens E, Janssens V, Rebollo A (2017) Identification of PP2A/SET binding sites and design of interfering peptides with potential clinical application. Int J Pept Res Ther 5:39–48
Andrini L, Marin GH, Inda AM, Bruzzoni-Giovanelli H, Garcia M, Errecalde J et al (2020) Anti-tumoral effect of a cell penetrating and interfering peptide targeting PP2A/SET interaction. Folia Med 62:31–36
Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ et al (2013) PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest 123:4144–4157
pubmed: 23999433
pmcid: 3784537
Hung MH, Chen KF (2017) Reprogramming the oncogenic response: SET protein as a potential therapeutic target in cancer. Expert Opin Ther Targets 21:685–694
pubmed: 28548025
Wlodarchak N, Xing Y (2016) PP2A as a master regulator of the cell cycle. Crit Rev Biochem Mol Biol 51:162–184
pubmed: 26906453
pmcid: 4905575
Seshacharyulu P, Pandey P, Datta K, Batra SK (2013) Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer. Cancer Lett 335:9–18
pubmed: 23454242
pmcid: 3665613
Janssens V, Goris J, Van Hoof C (2005) PP2A: the expected tumor suppressor. Curr Opin Genet Dev 15:34–41
pubmed: 15661531
Janssens V, Rebollo A (2012) The role and therapeutic potential of Ser/Thr phosphatase PP2A in apoptotic signalling networks in human cancer cells. Curr Mol Med 12:268–287
pubmed: 22300139
Ciccone M, Calin GA, Perrotti D (2015) From the biology of PP2A to the PADs for therapy of hematologic malignancies. Front Oncol 5:21–31
pubmed: 25763353
pmcid: 4329809
Chien W, Sun QY, Lee KL, Ding LW, Wuensche P, Torres-Fernandez LA et al (2015) Activation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer. Mol Oncol 9:889–905
pubmed: 25637283
pmcid: 4387089
Oaks JJ, Santhanam R, Walker CJ, Roof S, Harb JG, Ferenchak G et al (2013) Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. Blood 122:1923–1934
pubmed: 23926298
pmcid: 3772499
Parker MW, Linkugel AD, Vander Kooi CW (2013) Effect of C-terminal sequence on competitive semaphorin binding to neuropilin-1. J Mol Biol 425:4405–4414
pubmed: 23871893
pmcid: 4038064
Aoudjehane L, Boelle PY, Bisch G, Delelo R, Paye F, Scatton O et al (2016) Development of an in vitro model to test antifibrotic drugs on primary human liver myofibroblasts. Lab Investig 96:672–679
pubmed: 26950484
Aoudjehane L, Podevin P, Scatton O, Jaffray P, Dusanter-Fourt I, Feldmann G et al (2007) Interleukin-4 induces human hepatocyte apoptosis through a Fas-independent pathway. FASEB J 21:1433–1444
pubmed: 17283223
Thevenet P, Shen Y, Maupetit J, Guyon F, Derreumaux P, Tuffery P (2012) PEP-FOLD: an updated de novo structure prediction server for both linear and disulfide bonded cyclic peptides. Nucleic Acids Res 40:W288–W293
pubmed: 22581768
pmcid: 3394260
Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ (1990) Basic local alignment search tool. J Mol Biol 215:403–410
pubmed: 2231712
pmcid: 2231712
Zhang Y, Skolnick J (2005) TM-align: a protein structure alignment algorithm based on the TM-score. Nucleic Acids Res 33:2302–2309
pubmed: 15849316
pmcid: 1084323
DeLano WL (2002) Unraveling hot spots in binding interfaces: progress and challenges. Curr Opin Struct Biol 12:14–20
pubmed: 11839484